Incyte (INCY) Interest Expenses (2010 - 2026)
Incyte (INCY) reported Interest Expenses of $569000.0 for Q1 2026, down 13.79% on a YoY basis from $660000.0 in Q1 2025, and down 2.23% quarter-over-quarter from $582000.0 in Q4 2025.
Incyte (INCY) Interest Expenses (2010 - 2026) Analysis & Trends
Incyte has reported Interest Expenses for 17 years, with the latest figure at $569000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest Expenses fell 13.79% year-over-year to $569000.0; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (down 6.89% YoY), and the FY2025 full-year result was $2.4 million, up 6.49% from the prior year.
- Interest Expenses for Q1 2026 stood at $569000.0, down from $582000.0 in the prior quarter.
- The five-year high for Interest Expenses was $804000.0 in Q4 2023, with the low at $419000.0 in Q4 2024.
- Historically, Interest Expenses has averaged $617294.1 across 5 years, with a median of $641000.0 in 2022.
- Annual changes were most pronounced in 2022 — Interest Expenses soared 89.42% — and 2024, when it plunged 47.89%.
- Incyte's Interest Expenses stood at $667000.0 in 2022, then climbed by 20.54% to $804000.0 in 2023, then sank by 47.89% to $419000.0 in 2024, then surged by 38.9% to $582000.0 in 2025, then fell by 2.23% to $569000.0 in 2026.
- The last three Interest Expenses figures came in at $569000.0 (Q1 2026), $582000.0 (Q4 2025), and $592000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -332,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 61,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -5.58 Mn |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 569,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 569,000.00 |
| Mar 31, 2026 | 569,000.00 |
| Dec 31, 2025 | 582,000.00 |
| Dec 31, 2025 | 582,000.00 |
| Sep 30, 2025 | 592,000.00 |
| Sep 30, 2025 | 592,000.00 |
| Jun 30, 2025 | 594,000.00 |
| Jun 30, 2025 | 594,000.00 |
| Mar 31, 2025 | 660,000.00 |
| Mar 31, 2025 | 660,000.00 |
| Dec 31, 2024 | 419,000.00 |
| Dec 31, 2024 | 419,000.00 |
| Sep 30, 2024 | 774,000.00 |
| Sep 30, 2024 | 774,000.00 |
| Jun 30, 2024 | 657,000.00 |
| Jun 30, 2024 | 657,000.00 |
| Mar 31, 2024 | 430,000.00 |
| Mar 31, 2024 | 430,000.00 |
| Dec 31, 2023 | 804,000.00 |
| Dec 31, 2023 | 804,000.00 |